Pangea Laboratory Partners with Gene Solutions to Advance AI-Driven Cancer Detection Technologies

Pangea Laboratory and Gene Solutions Forge Alliance to Enhance Cancer Detection

Pangea Laboratory, a prominent player in molecular diagnostics and Next-Generation Sequencing (NGS), enters into a strategic collaboration with Gene Solutions to advance cancer detection through AI-driven liquid biopsy assays. This partnership aims to validate innovative diagnostic tools that will ultimately be offered as laboratory developed tests (LDTs) in CLIA/CAP-certified settings across the United States. By leveraging Pangea's extensive validation platform and regulatory expertise, the collaboration seeks to enhance the accuracy and accessibility of cancer diagnostics for patients in the U.S.

The focus of this collaboration centers on the validation of two flagship assays: SPOT-MAS, which is designed for Multi-Cancer Early Detection (MCED) and can identify early cancer signals from a single 10 mL blood draw across ten major cancer types and 75 subtypes, and K-4CARE, a precision oncology assay that combines genomic and transcriptomic profiling with Molecular Residual Disease (MRD) detection. This initiative is critical as it builds upon Pangea's existing Bladder CARE™ test, thereby expanding its diagnostic capabilities in oncology and addressing the urgent need for early cancer detection.

John Moore, CEO of Pangea, underscores the collaboration's potential to improve patient care through advanced diagnostic solutions, while Gene Solutions' Chief Data Science Officer, Dr. Hoa Giang, emphasizes the role of AI innovations in delivering affordable cancer detection tools. With Gene Solutions providing funding, standard operating procedures, and technical support from its facilities in Singapore and Vietnam, the partnership stands to significantly impact cancer diagnosis and treatment selection, marking a milestone in the quest for more effective cancer management strategies.

In a related development within the diagnostics landscape, Zepto Life Technology has launched the FungiFlex® Mold Panel, a plasma-based molecular diagnostic test that enables rapid detection of invasive fungal infections (IFIs). This innovative test identifies cell-free DNA from 14 clinically significant mold species within 24 hours, significantly improving upon traditional diagnostic methods that are often slow and invasive.

The FungiFlex® Mold Panel represents a crucial advancement for immunocompromised patients, offering timely clinical insights and reducing the need for invasive procedures. As Zepto Life continues to innovate in liquid biopsy technologies, this new test not only enhances patient care but also paves the way for future advancements in infectious disease diagnostics.